Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news: 8 news outlets
twitter: 10 tweeters

patent: 1 patent

Citations

dimensions_citation: 45 Dimensions

Readers on

mendeley: 74 Mendeley

Summary News Twitter Patents Dimensions citations

So far, Altmetric has seen 17 tweets from 10 users, with an upper bound of 24,371 followers.

La propuesta de desarrollar la inmunoterapia oncolitica, usando IVM para convertir las lesiones oncoligicas frías en calientes. Solo llego a eso. Convertirlas en calientes y el herpes y otras lesiones a la resina del Aciclovir. https://t.co/wQ0VRgqNYf

01 Jul 2022

Reply Retweet Favourite

RT @sitcancer: #JITC Research: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 h…

05 Sep 2019

Reply Retweet Favourite

#JITC Research: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 https://t.co/ng1pGana7V https://t.co/uzubLoetw7

05 Sep 2019

Reply Retweet Favourite

RT @sitcancer: #JITC Research: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 h…

30 Aug 2019

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 13 additional tweets.